Cell Biotech Co., Ltd. (KOSDAQ:049960)

Cell Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	8,142	4,757	7,884	8,458	9,860	9,600
Short-Term Investments	72,178	74,450	56,515	37,671	18,675	23,084
Trading Asset Securities	5,779	8,247	5,933	19,239	29,299	22,203
Cash & Short-Term Investments	86,098	87,454	70,332	65,368	57,834	54,887
Cash Growth	10.18%	24.34%	7.59%	13.03%	5.37%	-7.32%
Accounts Receivable	4,162	3,991	4,595	4,566	4,664	4,835
Other Receivables	1,241	682.88	943.86	583.11	268.43	283.39
Receivables	5,668	4,976	5,740	5,330	5,216	5,557
Inventory	5,131	4,203	4,122	4,102	3,589	3,503
Prepaid Expenses	188.11	287.27	691.85	500.5	292.5	218.67
Other Current Assets	260.14	228.19	1,044	354.58	587.81	746.72
Total Current Assets	97,346	97,148	81,929	75,655	67,519	64,913
Property, Plant & Equipment	29,521	30,463	32,937	33,638	34,057	36,602
Long-Term Investments	501.94	501.94	501.94	3,786	8,427	2
Other Intangible Assets	1,534	1,606	1,599	1,793	1,536	1,802
Long-Term Accounts Receivable	-0	0	0	0	0	0
Long-Term Deferred Tax Assets	216.96	216.96	182.29	449.3	751.56	1,395
Other Long-Term Assets	435.39	461.66	491.37	517.21	585.15	587.54
Total Assets	129,555	130,398	117,641	115,839	112,877	105,301
Accounts Payable	766.25	680.27	578.39	1,370	1,224	887.65
Accrued Expenses	978.55	481.51	489.15	443.91	470.95	496.32
Current Portion of Leases	617.46	650.28	621.14	600.78	402.89	658.65
Current Income Taxes Payable	621.75	1,404	-	1,038	814.73	-
Current Unearned Revenue	24.38	27.57	27.03	30.9	50.44	41.52
Other Current Liabilities	2,939	2,619	3,106	3,905	2,802	2,546
Total Current Liabilities	5,948	5,863	4,821	7,389	5,766	4,630
Long-Term Leases	115.53	366.66	934.17	357.79	423.49	686.44
Other Long-Term Liabilities	-	-	-	-	0	-
Total Liabilities	6,063	6,229	5,755	7,747	6,189	5,317
Common Stock	4,700	4,700	4,700	4,700	4,700	4,700
Additional Paid-In Capital	12,760	12,760	12,760	12,760	12,760	12,760
Retained Earnings	129,467	130,264	118,217	114,993	109,894	102,696
Treasury Stock	-23,978	-23,978	-23,978	-23,978	-20,258	-20,258
Comprehensive Income & Other	542.34	422.69	186.4	-382.91	-408.42	86.97
Shareholders' Equity	123,492	124,168	111,885	108,092	106,687	99,985
Total Liabilities & Equity	129,555	130,398	117,641	115,839	112,877	105,301
Total Debt	732.99	1,017	1,555	958.57	826.38	1,345
Net Cash (Debt)	85,365	86,437	68,777	64,409	57,007	53,542
Net Cash Growth	11.14%	25.68%	6.78%	12.98%	6.47%	-8.16%
Net Cash Per Share	12473.20	12629.74	10049.37	9342.06	8061.43	7547.42
Filing Date Shares Outstanding	6.84	6.84	6.84	6.84	7.07	7.07
Total Common Shares Outstanding	6.84	6.84	6.84	6.84	7.07	7.09
Working Capital	91,398	91,286	77,108	68,266	61,754	60,283
Book Value Per Share	18044.04	18142.94	16348.17	15793.91	15086.68	14094.07
Tangible Book Value	121,958	122,563	110,286	106,299	105,151	98,183
Tangible Book Value Per Share	17819.96	17908.31	16114.53	15531.88	14869.49	13840.05
Land	9,696	9,696	9,765	9,765	9,765	9,784
Buildings	20,269	19,675	19,537	13,349	13,854	14,389
Machinery	25,841	25,847	25,644	7,228	8,033	9,682
Construction In Progress	309.9	385.42	338.95	993.9	247.26	95

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.